A man creates a drug to treat schizophrenia in his garage using ChatGPT... What's the story?
Chemist Douglas Yao showcased an experimental drug compound that he said he designed with the help of the chatbot " ChatGBT " and manufactured in a chemistry lab he set up inside his garage, claiming it is aimed at treating schizophrenia. Yao calls the compound "PAC-3310" and says it was designed to be an improved version of the drug "Cobenfy" used to treat schizophrenia. Yao posted pictures of a vial containing a yellow powder, which he said was the first sample of "PAC-3310," explaining that "Shat GPT" helped design the compound, while he took over its manufacturing process in a laboratory he set up himself in his home garage, according to a report by Futurism, a website specializing in technology and science news, which was reviewed by Al Arabiya Business. Yao says he used artificial intelligence over the past year to design thousands of small drug molecules, then taught himself synthetic chemistry, and created about 100 compounds, before starting to test them on cells and mice. But what Yao has presented so far does not mean that "PAC-3310" has become a treatment for schizophrenia, as there is no clinical evidence to prove its effectiveness or safety in humans, and his description of it as an "improver" compared to "Cobenfy" remains a claim on his part and not a result proven by clinical trials. The development of any new drug is subject to a long course of testing before it is allowed to be tested on humans. It begins with laboratory and pre-clinical studies, then clinical trials, which usually go through three phases, before a formal application is submitted to the US Food and Drug Administration for approval to market it. Research data indicates that only a limited percentage of drug candidates that enter clinical trials eventually reach the approval stage, reflecting the difficulty of converting experimental compounds into approved drugs. Yao’s project is not limited to schizophrenia, as he says he is also working on another compound that targets Alzheimer’s disease, as part of a project to discover drugs with the help of artificial intelligence. Yao’s experiment sparked comments on the “X” platform, with some users pointing out the irony of using “ChatGPT” to help design drugs targeting psychiatric and neurological diseases, at a time when reports and concerns have increased about the link between interacting with AI chatbots and cases of psychosis or detachment from reality in some users.
0 Comments